Trending News

More News >

Education

Personal Finance How To Use TipRanks TipRanks Labs Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate TipRanks News Wire

TOOLS

Technical Analysis Screener

Top Analyst Stocks

Popular

Top Smart Score Stocks

Popular

AI Analyst Top Stocks

Daily Analyst Ratings

Daily Insiders Trades

Dividend Stocks

ETF Center

Top Gainers/losers/active ETFs

Trump Dashboard

New

Dividend Calculator

Options Profit Calculator

Dollar Cost Averaging

Compound Interest Calculator

Mortgage Calculator

Auto Loan Calculator

Student Loan Calculator

401k Retirement Calculator

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Education

About Us

Working with TipRanks

STOCKS

KYTX Stock Latest News

Company AnnouncementsKyverna Therapeutics Announces Board Member Resignation

4d ago

KYTX

PremiumRatings

Kyverna Therapeutics: Promising Potential in MS and MG with Strong Financials and Conservative Valuation

5d ago

KYTX

PremiumRatings

Kyverna Therapeutics’ KYV-101: Promising Efficacy and Safety in Multiple Sclerosis and Beyond

5d ago

KYTX

PremiumThe Fly

Kyverna Therapeutics announces updated data from Phase 1 IITs of KYV-101

5d ago

KYTX

PremiumThe Fly

Kyverna to present interim data from Phase 2 portion of KYSA-6 study at AANEM

14d ago

KYTX

PremiumRatingsKyverna Therapeutics, Inc.: Strategic Developments and Promising Clinical Trials Drive Buy Rating

28d ago

KYTX

Premium

Ratings

Kyverna Therapeutics’ KYV-101 Program Shows Promising Developments and Advances in Clinical Trials

29d ago

KYTX

Premium

Ratings

Kyverna Therapeutics’ KYV-101: Promising Data and Strategic Pathway Drive Buy Rating

1M ago

KYTX

PremiumThe Fly

Kyverna Therapeutics price target raised to $10 from $5 at H.C. Wainwright

1M ago

KYTX

PremiumRatings

Kyverna Therapeutics’ KYV-101: A Promising Investment in Addressing Unmet Needs in SPS and gMG

1M ago

KYTX

PremiumThe Fly

Kyverna Therapeutics to host KOL event on neuroimmunology CAR T franchise

1M ago

KYTX

PremiumThe Fly

Kyverna Therapeutics initiated with an Outperform at William Blair

1M ago

KYTX

PremiumRatingsKyverna Therapeutics: Promising Potential in Immune Cell Therapies with KYV-101

1M ago

KYTX

Premium

Ratings

Kyverna Therapeutics: Promising Clinical Progress and Strategic Advancements Drive Buy Rating

2M ago

KYTX

Premium

Ratings

Kyverna Therapeutics: Attractive Risk-Reward Profile with Upcoming Catalysts and Discounted Valuation

2M ago

KYTX

PremiumCompany Announcements

Kyverna Therapeutics Advances CAR T-Cell Therapy Trials

2M ago

KYTX

PremiumRatings

Kyverna Therapeutics: Promising Advancements in Neuroimmunology and Strategic Positioning for Market Leadership

2M ago

KYTX

PremiumThe Fly

Kyverna Therapeutics reports Q2 EPS (97c), consensus ($1.04)

2M ago

KYTX

PremiumCompany Announcements

Kyverna Therapeutics Appoints New Chief Financial Officer

3M ago

KYTX

PremiumThe FlyKyverna Therapeutics names Marc Grasso, M.D., as CFO

3M ago

KYTX

Premium

Company Announcements

Kyverna Therapeutics Holds 2025 Annual Stockholders Meeting

4M ago

KYTX

Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts

Premium

Weekend Updates

Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts

4M ago

FICO

KYTX

KYTX Stock Latest News

Trending

Indices

Stocks

ETFs